{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Morris J"],"funding":["CCR NIH HHS","Intramural NIH HHS","NCI NIH HHS","World Patent Application","NCI NIH"],"pagination":["625-631"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8030693"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(4)"],"pubmed_abstract":["In this article, 5-aza-4'-thio-2'-β-fluoro-2'-deoxycytidine (F-aza-T-dCyd, NSC801845), a novel cytidine analog, is first disclosed and compared with T-dCyd, F-T-dCyd, and aza-T-dCyd in cell culture and mouse xenograft studies in HCT-116 human colon carcinoma, OVCAR3 human ovarian carcinoma, NCI-H23 human NSCLC carcinoma, HL-60 human leukemia, and the PDX BL0382 bladder carcinoma. In three of five xenograft lines (HCT-116, HL-60, and BL-0382), F-aza-T-dCyd was more efficacious than aza-T-dCyd. Comparable activity was observed for these two agents against the NCI-H23 and OVCAR3 xenografts. In the HCT-116 study, F-aza-T-dCyd [10 mg/kg intraperitoneal (i.p.), QDx5 for four cycles], produced complete regression of the tumors in all mice with a response that proved durable beyond postimplant day"],"journal":["Molecular cancer therapeutics"],"pubmed_title":["F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd."],"pmcid":["PMC8030693"],"funding_grant_id":["HHSN261201700007I","HHSN261200800001E","HHSN261200800001C","HHSN261201700007C","Z99 CA999999","WO 2020/068657"],"pubmed_authors":["Lopez OD","Georgius K","Stotler H","Huang G","Kunkel MW","Hollingshead MG","Rudchenko V","Teicher BA","Carter J","Wishka DG","Collins JM","Morris J","Borgel S","Hoffman SN"],"additional_accession":[]},"is_claimable":false,"name":"F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd.","description":"In this article, 5-aza-4'-thio-2'-β-fluoro-2'-deoxycytidine (F-aza-T-dCyd, NSC801845), a novel cytidine analog, is first disclosed and compared with T-dCyd, F-T-dCyd, and aza-T-dCyd in cell culture and mouse xenograft studies in HCT-116 human colon carcinoma, OVCAR3 human ovarian carcinoma, NCI-H23 human NSCLC carcinoma, HL-60 human leukemia, and the PDX BL0382 bladder carcinoma. In three of five xenograft lines (HCT-116, HL-60, and BL-0382), F-aza-T-dCyd was more efficacious than aza-T-dCyd. Comparable activity was observed for these two agents against the NCI-H23 and OVCAR3 xenografts. In the HCT-116 study, F-aza-T-dCyd [10 mg/kg intraperitoneal (i.p.), QDx5 for four cycles], produced complete regression of the tumors in all mice with a response that proved durable beyond postimplant day","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-05-09T12:08:09.142Z","creation":"2022-02-11T11:38:40.894Z"},"accession":"S-EPMC8030693","cross_references":{"pubmed":["33811149"],"doi":["10.1158/1535-7163.mct-20-0738","10.1158/1535-7163.MCT-20-0738"]}}